NCT02593461 (DESTINy) is a Phase 3 clinical trial of Daifert in Infertility, sponsored by Forest Laboratories.

Who is sponsoring NCT02593461?

NCT02593461 is sponsored by Forest Laboratories.

What drugs are being tested in NCT02593461?

Interventions in NCT02593461: Daifert, Control Group.

What condition does NCT02593461 study?

NCT02593461 studies Infertility.

Is NCT02593461 still recruiting?

NCT02593461 is currently completed. Last updated 1 August 2017.

Last reviewed 2017-08-01 · How we verify

NCT02593461: DESTINy

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diafert® for Embryo Selection and Fertility Improvement

Completed Phase 3 Last updated 1 August 2017

What this trial tests

Phase 3 trial testing Daifert in Infertility in 14 participants. Completed in 7 April 2017.

Timeline

22 October 2015

Primary endpoint
15 December 2016

7 April 2017

Quick facts

Lead sponsor	Forest Laboratories
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	14
Start date	22 October 2015
Primary completion	15 December 2016
Estimated completion	7 April 2017
Sites	1 location across France

Drugs / interventions tested

Daifert
Control Group — full drug profile →

Conditions studied

Infertility — all drugs for Infertility →

Sponsor

Forest Laboratories — full company profile →

Who can join

18 and older, female only, with Infertility. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, single-center, single-blind, randomized, controlled, two-arm, interventional study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Daifert

Trials testing the same drug.

NCT02593513 — Diafert for Embryo Selection and Fertility Improvement (DESTINy) · Phase 3 · completed
NCT02586272 — Diafert for Embryo Selection and Fertility Improvement · Phase 3 · completed

Other recruiting trials for Infertility

Currently open trials in the same condition.

NCT07074015 — IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Speci · NA · recruiting
NCT07358468 — Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study · recruiting
NCT07340827 — A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH · Phase 3 · recruiting
NCT07369362 — To Investigate if the Harvester® Improves Sperm Motility and Blastocyst Utilization (the Percent of Fertilized Eggs That · NA · active not recruiting
NCT07153367 — Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauter · Phase 2 · recruiting

Other Forest Laboratories trials

Trials by the same sponsor.

NCT02788617 — Evaluation of the Efficacy of Diafert in Predicting Embryos' Potential to Develop to the Blastocyst Stage · completed
NCT02732327 — Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer · Phase 2 · terminated
NCT02670538 — Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode · Phase 3 · completed
NCT02670551 — Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depres · Phase 3 · completed
NCT02559570 — A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02593461 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Forest Laboratories
Last refreshed: 1 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02593461.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing